Sinovac Biotech Ltd. ( "Sinovac" or the " Company")(Nasdaq: SVA), a main supplier of biopharmaceutical items in China, today reported the China National Medical Products Administration (or NMPA) gave an item permit for its quadrivalent Influenza antibody (or QIV).

<span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.businesswire.com/news/home/20200624005762/en/Sinovac-Receives-Approval-China-Quadrivalent-Influenza-Vaccine">Sinovac anticipates that its QIV should be accessible to the China advertise for the 2020-2021 flu season. QIV contains two A strains and two B strains, suggested by the WHO, and the antibody ensures an objective gathering of 3 years and more established against the flu malady.</a></span>

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "The endorsement of QIV shows our progressing promise to create antibodies against influenza related illnesses. Notwithstanding the recently endorsed QIV, our authorized flu immunization portfolio comprises of Anflu®, China's first additive free trivalent flu infection split antibody; Panflu®, China's first pandemic flu infection (H5N1) inactivated antibody; and PANFLU.1®, the world's first flu A H1N1 flu infection split immunization. By utilizing our ability in flu immunization innovation, Sinovac can give an incredible assortment of arrangements against influenza related illness."

<strong>About Sinovac</strong>

<span style="color: #ff6600;"><a style="color: #ff6600;" href="http://www.sinovac.com/">Sinovac Biotech Ltd.</a></span> is a China-put together biopharmaceutical organization that concentrations with respect to the exploration, advancement, assembling and commercialization of antibodies that secure against human irresistible ailments.

Sinovac's item portfolio incorporates antibodies against enterovirus71 (EV71), hepatitis An and B, occasional flu, H5N1 pandemic flu (avian influenza), H1N1 flu (pig influenza), varicella immunization and mumps. Healive, the hepatitis An immunization fabricated by the Company, has passed the evaluation under WHO prequalification techniques in 2017. The EV71 immunization, an inventive antibody created by Sinovac against hand foot and mouth sickness brought about by EV71, was marketed in China in 2016. In 2009, Sinovac was the main organization worldwide to get endorsement for its H1N1 flu antibody, which it has provided to the Chinese Government's inoculation battle and storing program. The Company is likewise the main provider of the H5N1 pandemic flu immunization to the administration accumulating program.

The Company is building up various new items including a Sabin-strain inactivated polio immunization, pneumococcal polysaccharides antibody, a quadrivalent flu immunization and a SARS-CoV-2 (ordinarily alluded to as COVID-19) immunization. Sinovac essentially sells its antibodies in China, while likewise investigating development openings in global markets.

The Company is enlisting its items in more than 30 nations outside of China. For more data please observe the Company's site at <span style="color: #ff6600;"><a style="color: #ff6600;" href="http://www.sinovac.com/">www.sinovac.com.</a></span>